Clinical Trial Update: The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating bococizumab for reducing major cardiovascular events in high-risk subjects; study terminated with posted results in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease

Drugs mentioned

• Bococizumab (bococizumab)

Snippet

Sponsor: Pfizer | Conditions: Cardiovascular Disease | Phase 3 | Status: TERMINATED | Results posted: 2018-06-12